Nuvalent, Inc. (NUVL) Stock Competitors & Peer Comparison
See (NUVL) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NUVL | $92.02 | +0.74% | 6.6B | -14.87 | -$6.06 | N/A |
| NVO | $43.44 | +1.21% | 186.7B | 9.86 | $4.26 | +4.27% |
| VRTX | $439.72 | +3.44% | 108.7B | 25.46 | $16.83 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $627.78 | +4.12% | 63.8B | 15.12 | $40.94 | +0.59% |
| ARGX | $834.62 | +4.04% | 50.3B | 36.16 | $22.49 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $297.38 | +3.94% | 39.1B | 73.36 | $3.99 | N/A |
| RVMD | $158.22 | +4.57% | 33.2B | -21.97 | -$7.10 | N/A |
| RPRX | $55.59 | +2.93% | 23.6B | 28.93 | $1.90 | +1.65% |
Stock Comparison
NUVL vs NVO Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, NVO has a market cap of 186.7B. Regarding current trading prices, NUVL is priced at $92.02, while NVO trades at $43.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas NVO's P/E ratio is 9.86. In terms of profitability, NUVL's ROE is -0.43%, compared to NVO's ROE of +0.66%. Regarding short-term risk, NUVL is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check NVO's competition here
NUVL vs VRTX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, VRTX has a market cap of 108.7B. Regarding current trading prices, NUVL is priced at $92.02, while VRTX trades at $439.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas VRTX's P/E ratio is 25.46. In terms of profitability, NUVL's ROE is -0.43%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, NUVL is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check VRTX's competition here
NUVL vs VRNA Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, NUVL is priced at $92.02, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas VRNA's P/E ratio is -102.80. In terms of profitability, NUVL's ROE is -0.43%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, NUVL is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check VRNA's competition here
NUVL vs REGN Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, REGN has a market cap of 63.8B. Regarding current trading prices, NUVL is priced at $92.02, while REGN trades at $627.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas REGN's P/E ratio is 15.12. In terms of profitability, NUVL's ROE is -0.43%, compared to REGN's ROE of +0.14%. Regarding short-term risk, NUVL is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check REGN's competition here
NUVL vs ARGX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ARGX has a market cap of 50.3B. Regarding current trading prices, NUVL is priced at $92.02, while ARGX trades at $834.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ARGX's P/E ratio is 36.16. In terms of profitability, NUVL's ROE is -0.43%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, NUVL is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check ARGX's competition here
NUVL vs SGEN Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NUVL is priced at $92.02, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NUVL's ROE is -0.43%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NUVL is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check SGEN's competition here
NUVL vs ALNY Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ALNY has a market cap of 39.1B. Regarding current trading prices, NUVL is priced at $92.02, while ALNY trades at $297.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ALNY's P/E ratio is 73.36. In terms of profitability, NUVL's ROE is -0.43%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, NUVL is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ALNY's competition here
NUVL vs RVMD Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, RVMD has a market cap of 33.2B. Regarding current trading prices, NUVL is priced at $92.02, while RVMD trades at $158.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas RVMD's P/E ratio is -21.97. In terms of profitability, NUVL's ROE is -0.43%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, NUVL is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check RVMD's competition here
NUVL vs RPRX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, RPRX has a market cap of 23.6B. Regarding current trading prices, NUVL is priced at $92.02, while RPRX trades at $55.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas RPRX's P/E ratio is 28.93. In terms of profitability, NUVL's ROE is -0.43%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, NUVL is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check RPRX's competition here
NUVL vs UTHR Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, UTHR has a market cap of 23.3B. Regarding current trading prices, NUVL is priced at $92.02, while UTHR trades at $548.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas UTHR's P/E ratio is 20.31. In terms of profitability, NUVL's ROE is -0.43%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, NUVL is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check UTHR's competition here
NUVL vs INSM Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, INSM has a market cap of 22.5B. Regarding current trading prices, NUVL is priced at $92.02, while INSM trades at $103.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas INSM's P/E ratio is -18.03. In terms of profitability, NUVL's ROE is -0.43%, compared to INSM's ROE of -1.30%. Regarding short-term risk, NUVL is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check INSM's competition here
NUVL vs BNTX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, BNTX has a market cap of 22.4B. Regarding current trading prices, NUVL is priced at $92.02, while BNTX trades at $89.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas BNTX's P/E ratio is -14.97. In terms of profitability, NUVL's ROE is -0.43%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, NUVL is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check BNTX's competition here
NUVL vs ROIV Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ROIV has a market cap of 20.6B. Regarding current trading prices, NUVL is priced at $92.02, while ROIV trades at $28.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ROIV's P/E ratio is -53.15. In terms of profitability, NUVL's ROE is -0.43%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, NUVL is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check ROIV's competition here
NUVL vs BGNE Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NUVL is priced at $92.02, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NUVL's ROE is -0.43%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, NUVL is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check BGNE's competition here
NUVL vs INCY Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, INCY has a market cap of 19.6B. Regarding current trading prices, NUVL is priced at $92.02, while INCY trades at $99.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas INCY's P/E ratio is 13.84. In terms of profitability, NUVL's ROE is -0.43%, compared to INCY's ROE of +0.29%. Regarding short-term risk, NUVL is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check INCY's competition here
NUVL vs MRNA Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, MRNA has a market cap of 19.5B. Regarding current trading prices, NUVL is priced at $92.02, while MRNA trades at $49.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas MRNA's P/E ratio is -6.02. In terms of profitability, NUVL's ROE is -0.43%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, NUVL is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check MRNA's competition here
NUVL vs DNA-WT Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NUVL is priced at $92.02, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NUVL's ROE is -0.43%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, NUVL is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check DNA-WT's competition here
NUVL vs NBIX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, NBIX has a market cap of 16.6B. Regarding current trading prices, NUVL is priced at $92.02, while NBIX trades at $167.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas NBIX's P/E ratio is 25.40. In terms of profitability, NUVL's ROE is -0.43%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, NUVL is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check NBIX's competition here
NUVL vs GMAB Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, GMAB has a market cap of 14.7B. Regarding current trading prices, NUVL is priced at $92.02, while GMAB trades at $24.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas GMAB's P/E ratio is 18.23. In terms of profitability, NUVL's ROE is -0.43%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, NUVL is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check GMAB's competition here
NUVL vs JAZZ Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, JAZZ has a market cap of 14.5B. Regarding current trading prices, NUVL is priced at $92.02, while JAZZ trades at $235.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas JAZZ's P/E ratio is 1924.42. In terms of profitability, NUVL's ROE is -0.43%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, NUVL is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check JAZZ's competition here
NUVL vs ASND Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ASND has a market cap of 13.4B. Regarding current trading prices, NUVL is priced at $92.02, while ASND trades at $221.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ASND's P/E ratio is 24.58. In terms of profitability, NUVL's ROE is -0.43%, compared to ASND's ROE of -56.42%. Regarding short-term risk, NUVL is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ASND's competition here
NUVL vs EXEL Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, EXEL has a market cap of 13B. Regarding current trading prices, NUVL is priced at $92.02, while EXEL trades at $51.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas EXEL's P/E ratio is 17.09. In terms of profitability, NUVL's ROE is -0.43%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, NUVL is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check EXEL's competition here
NUVL vs BBIO Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, BBIO has a market cap of 12.8B. Regarding current trading prices, NUVL is priced at $92.02, while BBIO trades at $65.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas BBIO's P/E ratio is -17.51. In terms of profitability, NUVL's ROE is -0.43%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, NUVL is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check BBIO's competition here
NUVL vs KRTX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NUVL is priced at $92.02, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NUVL's ROE is -0.43%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NUVL is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check KRTX's competition here
NUVL vs IONS Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, NUVL is priced at $92.02, while IONS trades at $74.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas IONS's P/E ratio is -36.73. In terms of profitability, NUVL's ROE is -0.43%, compared to IONS's ROE of -0.59%. Regarding short-term risk, NUVL is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check IONS's competition here
NUVL vs AXSM Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, AXSM has a market cap of 12B. Regarding current trading prices, NUVL is priced at $92.02, while AXSM trades at $233.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas AXSM's P/E ratio is -62.60. In terms of profitability, NUVL's ROE is -0.43%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, NUVL is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check AXSM's competition here
NUVL vs SMMT Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, SMMT has a market cap of 11.7B. Regarding current trading prices, NUVL is priced at $92.02, while SMMT trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas SMMT's P/E ratio is -9.48. In terms of profitability, NUVL's ROE is -0.43%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, NUVL is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check SMMT's competition here
NUVL vs RNAM Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, NUVL is priced at $92.02, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas RNAM's P/E ratio is -17.39. In terms of profitability, NUVL's ROE is -0.43%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, NUVL is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check RNAM's competition here
NUVL vs MDGL Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, MDGL has a market cap of 11.3B. Regarding current trading prices, NUVL is priced at $92.02, while MDGL trades at $496.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas MDGL's P/E ratio is -36.21. In terms of profitability, NUVL's ROE is -0.43%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, NUVL is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check MDGL's competition here
NUVL vs BMRN Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, NUVL is priced at $92.02, while BMRN trades at $55.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas BMRN's P/E ratio is 39.32. In terms of profitability, NUVL's ROE is -0.43%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, NUVL is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check BMRN's competition here
NUVL vs ARWR Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ARWR has a market cap of 10.2B. Regarding current trading prices, NUVL is priced at $92.02, while ARWR trades at $72.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ARWR's P/E ratio is -31.96. In terms of profitability, NUVL's ROE is -0.43%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, NUVL is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ARWR's competition here
NUVL vs RXDX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NUVL is priced at $92.02, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NUVL's ROE is -0.43%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NUVL is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check RXDX's competition here
NUVL vs KRYS Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, NUVL is priced at $92.02, while KRYS trades at $303.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas KRYS's P/E ratio is 40.35. In terms of profitability, NUVL's ROE is -0.43%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, NUVL is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check KRYS's competition here
NUVL vs CYTK Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CYTK has a market cap of 8.8B. Regarding current trading prices, NUVL is priced at $92.02, while CYTK trades at $71.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CYTK's P/E ratio is -10.32. In terms of profitability, NUVL's ROE is -0.43%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, NUVL is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CYTK's competition here
NUVL vs IMGN Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NUVL is priced at $92.02, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NUVL's ROE is -0.43%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, NUVL is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check IMGN's competition here
NUVL vs BPMC Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NUVL is priced at $92.02, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NUVL's ROE is -0.43%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, NUVL is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check BPMC's competition here
NUVL vs HALO Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, HALO has a market cap of 8.3B. Regarding current trading prices, NUVL is priced at $92.02, while HALO trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas HALO's P/E ratio is 24.50. In terms of profitability, NUVL's ROE is -0.43%, compared to HALO's ROE of +1.26%. Regarding short-term risk, NUVL is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check HALO's competition here
NUVL vs CERE Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NUVL is priced at $92.02, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CERE's P/E ratio is -16.47. In terms of profitability, NUVL's ROE is -0.43%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NUVL is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CERE's competition here
NUVL vs TECH Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, TECH has a market cap of 8B. Regarding current trading prices, NUVL is priced at $92.02, while TECH trades at $51.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas TECH's P/E ratio is 72.64. In terms of profitability, NUVL's ROE is -0.43%, compared to TECH's ROE of +0.05%. Regarding short-term risk, NUVL is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check TECH's competition here
NUVL vs CORT Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CORT has a market cap of 7.8B. Regarding current trading prices, NUVL is priced at $92.02, while CORT trades at $73.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CORT's P/E ratio is 207.57. In terms of profitability, NUVL's ROE is -0.43%, compared to CORT's ROE of +0.08%. Regarding short-term risk, NUVL is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CORT's competition here
NUVL vs IBRX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, NUVL is priced at $92.02, while IBRX trades at $7.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas IBRX's P/E ratio is -8.45. In terms of profitability, NUVL's ROE is -0.43%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, NUVL is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check IBRX's competition here
NUVL vs MTSR Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, NUVL is priced at $92.02, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas MTSR's P/E ratio is -23.58. In terms of profitability, NUVL's ROE is -0.43%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, NUVL is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check MTSR's competition here
NUVL vs ALKS Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ALKS has a market cap of 7.1B. Regarding current trading prices, NUVL is priced at $92.02, while ALKS trades at $43.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ALKS's P/E ratio is 47.51. In terms of profitability, NUVL's ROE is -0.43%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, NUVL is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ALKS's competition here
NUVL vs MRUS Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, NUVL is priced at $92.02, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas MRUS's P/E ratio is -17.05. In terms of profitability, NUVL's ROE is -0.43%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, NUVL is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check MRUS's competition here
NUVL vs PCVX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, PCVX has a market cap of 6.8B. Regarding current trading prices, NUVL is priced at $92.02, while PCVX trades at $47.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas PCVX's P/E ratio is -6.81. In terms of profitability, NUVL's ROE is -0.43%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, NUVL is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check PCVX's competition here
NUVL vs ACLX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, NUVL is priced at $92.02, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ACLX's P/E ratio is -28.27. In terms of profitability, NUVL's ROE is -0.43%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, NUVL is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check ACLX's competition here
NUVL vs LEGN Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, LEGN has a market cap of 6.7B. Regarding current trading prices, NUVL is priced at $92.02, while LEGN trades at $35.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas LEGN's P/E ratio is -26.07. In terms of profitability, NUVL's ROE is -0.43%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, NUVL is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check LEGN's competition here
NUVL vs RETA Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NUVL is priced at $92.02, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas RETA's P/E ratio is -66.29. In terms of profitability, NUVL's ROE is -0.43%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NUVL is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check RETA's competition here
NUVL vs IMVT Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, IMVT has a market cap of 6.4B. Regarding current trading prices, NUVL is priced at $92.02, while IMVT trades at $31.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas IMVT's P/E ratio is -11.25. In terms of profitability, NUVL's ROE is -0.43%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, NUVL is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check IMVT's competition here
NUVL vs CNTA Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, NUVL is priced at $92.02, while CNTA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CNTA's P/E ratio is -22.39. In terms of profitability, NUVL's ROE is -0.43%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, NUVL is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CNTA's competition here
NUVL vs TGTX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, TGTX has a market cap of 6.1B. Regarding current trading prices, NUVL is priced at $92.02, while TGTX trades at $41.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas TGTX's P/E ratio is 14.02. In terms of profitability, NUVL's ROE is -0.43%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, NUVL is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check TGTX's competition here
NUVL vs PTGX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, PTGX has a market cap of 6.1B. Regarding current trading prices, NUVL is priced at $92.02, while PTGX trades at $98.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas PTGX's P/E ratio is -52.71. In terms of profitability, NUVL's ROE is -0.43%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, NUVL is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check PTGX's competition here
NUVL vs KYMR Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, KYMR has a market cap of 6B. Regarding current trading prices, NUVL is priced at $92.02, while KYMR trades at $74.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas KYMR's P/E ratio is -20.45. In terms of profitability, NUVL's ROE is -0.43%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, NUVL is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check KYMR's competition here
NUVL vs ABVX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ABVX has a market cap of 5.9B. Regarding current trading prices, NUVL is priced at $92.02, while ABVX trades at $97.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ABVX's P/E ratio is -16.79. In terms of profitability, NUVL's ROE is -0.43%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, NUVL is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ABVX's competition here
NUVL vs PRAX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, PRAX has a market cap of 5.9B. Regarding current trading prices, NUVL is priced at $92.02, while PRAX trades at $275.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas PRAX's P/E ratio is -20.82. In terms of profitability, NUVL's ROE is -0.43%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, NUVL is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check PRAX's competition here
NUVL vs RYTM Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, NUVL is priced at $92.02, while RYTM trades at $85.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas RYTM's P/E ratio is -27.06. In terms of profitability, NUVL's ROE is -0.43%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, NUVL is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check RYTM's competition here
NUVL vs PTCT Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, NUVL is priced at $92.02, while PTCT trades at $70.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas PTCT's P/E ratio is -27.04. In terms of profitability, NUVL's ROE is -0.43%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, NUVL is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check PTCT's competition here
NUVL vs CDTX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, NUVL is priced at $92.02, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CDTX's P/E ratio is -19.77. In terms of profitability, NUVL's ROE is -0.43%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, NUVL is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CDTX's competition here
NUVL vs ABCM Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NUVL is priced at $92.02, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NUVL's ROE is -0.43%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NUVL is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check ABCM's competition here
NUVL vs COGT Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, NUVL is priced at $92.02, while COGT trades at $33.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas COGT's P/E ratio is -14.87. In terms of profitability, NUVL's ROE is -0.43%, compared to COGT's ROE of -0.83%. Regarding short-term risk, NUVL is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check COGT's competition here
NUVL vs ISEE Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NUVL is priced at $92.02, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NUVL's ROE is -0.43%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NUVL is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check ISEE's competition here
NUVL vs BLTE Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, BLTE has a market cap of 5.5B. Regarding current trading prices, NUVL is priced at $92.02, while BLTE trades at $137.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas BLTE's P/E ratio is -53.82. In terms of profitability, NUVL's ROE is -0.43%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, NUVL is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check BLTE's competition here
NUVL vs SRRK Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, NUVL is priced at $92.02, while SRRK trades at $45.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas SRRK's P/E ratio is -12.94. In terms of profitability, NUVL's ROE is -0.43%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, NUVL is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check SRRK's competition here
NUVL vs APLS Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, NUVL is priced at $92.02, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas APLS's P/E ratio is 38.35. In terms of profitability, NUVL's ROE is -0.43%, compared to APLS's ROE of +0.40%. Regarding short-term risk, NUVL is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check APLS's competition here
NUVL vs APGE Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, APGE has a market cap of 5.2B. Regarding current trading prices, NUVL is priced at $92.02, while APGE trades at $85.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas APGE's P/E ratio is -19.44. In terms of profitability, NUVL's ROE is -0.43%, compared to APGE's ROE of -0.33%. Regarding short-term risk, NUVL is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check APGE's competition here
NUVL vs CRSP Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, NUVL is priced at $92.02, while CRSP trades at $54.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CRSP's P/E ratio is -8.44. In terms of profitability, NUVL's ROE is -0.43%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, NUVL is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CRSP's competition here
NUVL vs LQDA Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, LQDA has a market cap of 5B. Regarding current trading prices, NUVL is priced at $92.02, while LQDA trades at $56.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas LQDA's P/E ratio is 327.59. In terms of profitability, NUVL's ROE is -0.43%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, NUVL is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check LQDA's competition here
NUVL vs FBIOX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, FBIOX has a market cap of 4.9B. Regarding current trading prices, NUVL is priced at $92.02, while FBIOX trades at $24.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas FBIOX's P/E ratio is N/A. In terms of profitability, NUVL's ROE is -0.43%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, NUVL is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check FBIOX's competition here
NUVL vs CGON Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CGON has a market cap of 4.8B. Regarding current trading prices, NUVL is priced at $92.02, while CGON trades at $55.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CGON's P/E ratio is -23.26. In terms of profitability, NUVL's ROE is -0.43%, compared to CGON's ROE of -0.23%. Regarding short-term risk, NUVL is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CGON's competition here
NUVL vs TERN Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, NUVL is priced at $92.02, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas TERN's P/E ratio is -51.41. In terms of profitability, NUVL's ROE is -0.43%, compared to TERN's ROE of -0.20%. Regarding short-term risk, NUVL is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check TERN's competition here
NUVL vs LGND Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, LGND has a market cap of 4.7B. Regarding current trading prices, NUVL is priced at $92.02, while LGND trades at $236.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas LGND's P/E ratio is 30.56. In terms of profitability, NUVL's ROE is -0.43%, compared to LGND's ROE of +0.16%. Regarding short-term risk, NUVL is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check LGND's competition here
NUVL vs MIRM Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, MIRM has a market cap of 4.6B. Regarding current trading prices, NUVL is priced at $92.02, while MIRM trades at $93.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas MIRM's P/E ratio is -6.75. In terms of profitability, NUVL's ROE is -0.43%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, NUVL is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check MIRM's competition here
NUVL vs FOLD Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, NUVL is priced at $92.02, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas FOLD's P/E ratio is -161.00. In terms of profitability, NUVL's ROE is -0.43%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, NUVL is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check FOLD's competition here
NUVL vs AKRO Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, NUVL is priced at $92.02, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas AKRO's P/E ratio is -14.57. In terms of profitability, NUVL's ROE is -0.43%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, NUVL is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check AKRO's competition here
NUVL vs ALPN Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NUVL is priced at $92.02, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NUVL's ROE is -0.43%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NUVL is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check ALPN's competition here
NUVL vs SYRE Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, NUVL is priced at $92.02, while SYRE trades at $76.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas SYRE's P/E ratio is -34.60. In terms of profitability, NUVL's ROE is -0.43%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, NUVL is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check SYRE's competition here
NUVL vs CAI Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, NUVL is priced at $92.02, while CAI trades at $15.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CAI's P/E ratio is -5.61. In terms of profitability, NUVL's ROE is -0.43%, compared to CAI's ROE of +0.06%. Regarding short-term risk, NUVL is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CAI's competition here
NUVL vs CELC Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, NUVL is priced at $92.02, while CELC trades at $87.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CELC's P/E ratio is -22.81. In terms of profitability, NUVL's ROE is -0.43%, compared to CELC's ROE of -2.45%. Regarding short-term risk, NUVL is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CELC's competition here
NUVL vs OPT Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NUVL is priced at $92.02, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas OPT's P/E ratio is -1.52. In terms of profitability, NUVL's ROE is -0.43%, compared to OPT's ROE of +1.09%. Regarding short-term risk, NUVL is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check OPT's competition here
NUVL vs XENE Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, NUVL is priced at $92.02, while XENE trades at $54.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas XENE's P/E ratio is -11.37. In terms of profitability, NUVL's ROE is -0.43%, compared to XENE's ROE of -0.49%. Regarding short-term risk, NUVL is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check XENE's competition here
NUVL vs TVTX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, TVTX has a market cap of 4.2B. Regarding current trading prices, NUVL is priced at $92.02, while TVTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas TVTX's P/E ratio is -90.40. In terms of profitability, NUVL's ROE is -0.43%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, NUVL is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check TVTX's competition here
NUVL vs MRTX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NUVL is priced at $92.02, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NUVL's ROE is -0.43%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NUVL is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check MRTX's competition here
NUVL vs ERAS Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ERAS has a market cap of 4.1B. Regarding current trading prices, NUVL is priced at $92.02, while ERAS trades at $13.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ERAS's P/E ratio is -14.17. In terms of profitability, NUVL's ROE is -0.43%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, NUVL is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ERAS's competition here
NUVL vs MANE Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, MANE has a market cap of 4B. Regarding current trading prices, NUVL is priced at $92.02, while MANE trades at $97.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas MANE's P/E ratio is -36.37. In terms of profitability, NUVL's ROE is -0.43%, compared to MANE's ROE of -0.95%. Regarding short-term risk, NUVL is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check MANE's competition here
NUVL vs EWTX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, EWTX has a market cap of 3.9B. Regarding current trading prices, NUVL is priced at $92.02, while EWTX trades at $37.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas EWTX's P/E ratio is -21.81. In terms of profitability, NUVL's ROE is -0.43%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, NUVL is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check EWTX's competition here
NUVL vs VCYT Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, NUVL is priced at $92.02, while VCYT trades at $49.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas VCYT's P/E ratio is 45.08. In terms of profitability, NUVL's ROE is -0.43%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, NUVL is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check VCYT's competition here
NUVL vs CPRX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, NUVL is priced at $92.02, while CPRX trades at $31.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CPRX's P/E ratio is 18.08. In terms of profitability, NUVL's ROE is -0.43%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, NUVL is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CPRX's competition here
NUVL vs NAMS Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, NAMS has a market cap of 3.8B. Regarding current trading prices, NUVL is priced at $92.02, while NAMS trades at $32.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas NAMS's P/E ratio is -18.04. In terms of profitability, NUVL's ROE is -0.43%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, NUVL is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check NAMS's competition here
NUVL vs RYZB Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NUVL is priced at $92.02, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NUVL's ROE is -0.43%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NUVL is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check RYZB's competition here
NUVL vs CBAY Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NUVL is priced at $92.02, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NUVL's ROE is -0.43%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, NUVL is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CBAY's competition here
NUVL vs ACAD Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, NUVL is priced at $92.02, while ACAD trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas ACAD's P/E ratio is 9.70. In terms of profitability, NUVL's ROE is -0.43%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, NUVL is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check ACAD's competition here
NUVL vs KNSA Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, NUVL is priced at $92.02, while KNSA trades at $48.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas KNSA's P/E ratio is 52.58. In terms of profitability, NUVL's ROE is -0.43%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, NUVL is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check KNSA's competition here
NUVL vs DNTH Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, NUVL is priced at $92.02, while DNTH trades at $87.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas DNTH's P/E ratio is -20.09. In terms of profitability, NUVL's ROE is -0.43%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, NUVL is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check DNTH's competition here
NUVL vs SWTX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, NUVL is priced at $92.02, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas SWTX's P/E ratio is -13.78. In terms of profitability, NUVL's ROE is -0.43%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, NUVL is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check SWTX's competition here
NUVL vs CRNX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, CRNX has a market cap of 3.5B. Regarding current trading prices, NUVL is priced at $92.02, while CRNX trades at $34.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas CRNX's P/E ratio is -6.44. In terms of profitability, NUVL's ROE is -0.43%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, NUVL is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CRNX's competition here
NUVL vs VKTX Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, VKTX has a market cap of 3.4B. Regarding current trading prices, NUVL is priced at $92.02, while VKTX trades at $29.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas VKTX's P/E ratio is -7.07. In terms of profitability, NUVL's ROE is -0.43%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, NUVL is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check VKTX's competition here
NUVL vs DNLI Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, NUVL is priced at $92.02, while DNLI trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas DNLI's P/E ratio is -6.83. In terms of profitability, NUVL's ROE is -0.43%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, NUVL is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check DNLI's competition here
NUVL vs BEAM Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, BEAM has a market cap of 3B. Regarding current trading prices, NUVL is priced at $92.02, while BEAM trades at $30.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas BEAM's P/E ratio is -60.31. In terms of profitability, NUVL's ROE is -0.43%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, NUVL is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check BEAM's competition here
NUVL vs DYN Comparison June 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 6.6B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, NUVL is priced at $92.02, while DYN trades at $18.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -14.87, whereas DYN's P/E ratio is -5.71. In terms of profitability, NUVL's ROE is -0.43%, compared to DYN's ROE of -0.58%. Regarding short-term risk, NUVL is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check DYN's competition here